Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Development and Replication of a Genome-Wide Polygenic Risk Score for Chronic Back Pain. / Tsepilov, Yakov A; Elgaeva, Elizaveta E; Nostaeva, Arina V и др.
в: Journal of Personalized Medicine, Том 13, № 6, 977, 10.06.2023.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Development and Replication of a Genome-Wide Polygenic Risk Score for Chronic Back Pain
AU - Tsepilov, Yakov A
AU - Elgaeva, Elizaveta E
AU - Nostaeva, Arina V
AU - Compte, Roger
AU - Kuznetsov, Ivan A
AU - Karssen, Lennart C
AU - Freidin, Maxim B
AU - Suri, Pradeep
AU - Williams, Frances M K
AU - Aulchenko, Yurii S
N1 - Funding: The work of R.C. has been supported by funding from Versus Arthritis (Grant Number 22467) and Marie Skłodowska Curie International Training Network (ITN) “disc4all” (H2020-MSCA-ITN-ETN-2020 GA: 9557). Tsepilov and Elgaeva were supported by the Russian Science Foundation (RSF) grant No. 22-15-20037 and Government of the Novosibirsk region. Suri is an employee of the VA Puget Sound Health Care System and is Director of the University of Washington Clinical Learning, Ev-idence and Research (CLEAR) Center Resource Core, which is funded by NIAMS/NIH P30AR072572. The contents of this work do not represent the views of the US Department of Veterans Affairs, the National Institutes of Health, or the US Government. The data analysis was performed using computational resources of the “Bioinformatics” Joint Computational Center supported by the budget project No. FWNR-2022-0020.
PY - 2023/6/10
Y1 - 2023/6/10
N2 - Chronic back pain (CBP) is a complex heritable trait and a major cause of disability worldwide. We developed and validated a genome-wide polygenic risk score (PRS) for CBP using a large-scale GWAS based on UK Biobank participants of European ancestry (N = 265,000). The PRS showed poor overall predictive ability (AUC = 0.56 and OR = 1.24 per SD, 95% CI: 1.22-1.26), but individuals from the 99th percentile of PRS distribution had a nearly two-fold increased risk of CBP (OR = 1.82, 95% CI: 1.60-2.06). We validated the PRS on an independent TwinsUK sample, obtaining a similar magnitude of effect. The PRS was significantly associated with various ICD-10 and OPCS-4 diagnostic codes, including chronic ischemic heart disease (OR = 1.1, p-value = 4.8 × 10-15), obesity, metabolism-related traits, spine disorders, disc degeneration, and arthritis-related disorders. PRS and environment interaction analysis with twelve known CBP risk factors revealed no significant results, suggesting that the magnitude of G × E interactions with studied factors is small. The limited predictive ability of the PRS that we developed is likely explained by the complexity, heterogeneity, and polygenicity of CBP, for which sample sizes of a few hundred thousand are insufficient to estimate small genetic effects robustly.
AB - Chronic back pain (CBP) is a complex heritable trait and a major cause of disability worldwide. We developed and validated a genome-wide polygenic risk score (PRS) for CBP using a large-scale GWAS based on UK Biobank participants of European ancestry (N = 265,000). The PRS showed poor overall predictive ability (AUC = 0.56 and OR = 1.24 per SD, 95% CI: 1.22-1.26), but individuals from the 99th percentile of PRS distribution had a nearly two-fold increased risk of CBP (OR = 1.82, 95% CI: 1.60-2.06). We validated the PRS on an independent TwinsUK sample, obtaining a similar magnitude of effect. The PRS was significantly associated with various ICD-10 and OPCS-4 diagnostic codes, including chronic ischemic heart disease (OR = 1.1, p-value = 4.8 × 10-15), obesity, metabolism-related traits, spine disorders, disc degeneration, and arthritis-related disorders. PRS and environment interaction analysis with twelve known CBP risk factors revealed no significant results, suggesting that the magnitude of G × E interactions with studied factors is small. The limited predictive ability of the PRS that we developed is likely explained by the complexity, heterogeneity, and polygenicity of CBP, for which sample sizes of a few hundred thousand are insufficient to estimate small genetic effects robustly.
UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85163766350&origin=inward&txGid=ef12429e37e093996fca2cdbc910f6b8
UR - https://www.mendeley.com/catalogue/00da0d05-a4e1-3a65-8ea7-8b087ba76fa3/
U2 - 10.3390/jpm13060977
DO - 10.3390/jpm13060977
M3 - Article
C2 - 37373966
VL - 13
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
SN - 2075-4426
IS - 6
M1 - 977
ER -
ID: 53349291